PMCB insider filings
PharmaCyte Biotech, Inc. — 27 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-07-17. Screen PMCB transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for PMCB between 2026-07-26 and 2026-10-24. The table below lists the most recent filings on record.
Recent insider filings — PharmaCyte Biotech, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-17 | 4/A | WALKER WAYNE REMELL — Director | Other (J): 0 (derivative) | EDGAR |
| 2026-07-17 | 4/A | Abecassis Michael M — Director | Other (J): 0 (derivative) | EDGAR |
| 2026-07-17 | 4/A | SCHECHTER JONATHAN — Director | Other (J): 0 (derivative) | EDGAR |
| 2026-07-17 | 4/A | WEINSTEIN ROBERT — Director | Other (J): 0 (derivative) | EDGAR |
| 2026-04-02 | 4 | WEINSTEIN ROBERT — Director | Grant/award (A): 119,170 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | WALKER WAYNE REMELL — Director | Grant/award (A): 119,170 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | SCHECHTER JONATHAN — Director | Grant/award (A): 119,170 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Abecassis Michael M — Director | Grant/award (A): 119,170 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Silverman Joshua — CEO and President, Director | Purchase (P): 30,000 @ $0.78 · Purchase (P): 30,000 @ $0.79 · Purchase (P): 40,000 @ $0.83 | EDGAR |
| 2026-01-07 | 4 | SCHECHTER JONATHAN — Director | Purchase (P): 20,000 @ $0.78 · Purchase (P): 20,000 @ $0.79 · Purchase (P): 20,000 @ $0.84 | EDGAR |
| 2025-12-12 | 4 | WEINSTEIN ROBERT — Director | Grant/award (A): 75,000 @ $0 · Tax withholding (F): 33,750 @ $1.02 · Grant/award (A): 63,233 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | WALKER WAYNE REMELL — Director | Grant/award (A): 37,500 @ $0 · Tax withholding (F): 16,875 @ $1.02 · Grant/award (A): 63,233 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | Silverman Joshua — CEO and President, Director | Grant/award (A): 575,000 @ $0 · Tax withholding (F): 258,750 @ $1.02 | EDGAR |
| 2025-12-12 | 4 | SCHECHTER JONATHAN — Director | Grant/award (A): 150,000 @ $0 · Tax withholding (F): 67,500 @ $1.02 · Grant/award (A): 63,233 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | Abecassis Michael M — Director | Grant/award (A): 37,500 @ $0 · Tax withholding (F): 16,875 @ $1.02 · Grant/award (A): 63,233 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | WEINSTEIN ROBERT — Director | Grant/award (A): 38,009 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | WALKER WAYNE REMELL — Director | Grant/award (A): 38,009 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | SCHECHTER JONATHAN — Director | Grant/award (A): 38,009 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | Abecassis Michael M — Director | Grant/award (A): 38,009 (derivative) @ $0 | EDGAR |
| 2023-11-22 | 4 | WEINSTEIN ROBERT — Director | Grant/award (A): 61,248 (derivative) @ $0 | EDGAR |
| 2023-11-22 | 4 | WALKER WAYNE REMELL — Director | Grant/award (A): 61,248 (derivative) @ $0 | EDGAR |
| 2023-11-22 | 4 | Trujillo Carlos — Chief Financial Officer, Director | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2023-11-22 | 4 | Silverman Joshua — Interim CEO, Interim President, Director | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2023-11-22 | 4 | SCHECHTER JONATHAN — Director | Grant/award (A): 61,248 (derivative) @ $0 | EDGAR |
| 2023-11-22 | 4 | Abecassis Michael M — Director | Grant/award (A): 61,248 (derivative) @ $0 | EDGAR |
| 2022-12-30 | 4 | Farb Daniel Stuart — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2022-12-30 | 4 | Allen Daniel — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — PharmaCyte Biotech, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-16 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-05 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2025-11-18 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-31 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-04-24 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-02-26 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PMCB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs